ÍNDICE ROX EM PACIENTES COM COVID-19 QUE USARAM TERAPIA DE ALTO FLUXO E ELMO
DOI:
https://doi.org/10.54620/cadesp.v15i2.671Palavras-chave:
COVID-19, Ventilação Não Invasiva, Insuficiência respiratóriaResumo
Avaliar o índice ROX na monitorização de pacientes com insuficiência respiratória por COVID-19. Estudo transversal realizado no Hospital de Doenças Infecciosas São José, no Ceará. Foram incluídos indivíduos com COVID-19, internados no período de janeiro a julho, que utilizaram terapia de alto fluxo de oxigênio (TAF) combinado com ELMO. A coleta de dados ocorreu através da revisão de prontuários. Os dados foram analisados através do software Excel Microsoft 365. No período do estudo, 40 pacientes foram incluídos nesta pesquisa. A maioria era do sexo masculino (67,5%). A média de idade foi de 51,9 anos; 65% dos pacientes obtiveram sucesso com a terapia TAF/ELMO. Índice ROX foi preditor de sucesso ou falha na 24ª e 48ª hora. Houve uma forte correlação entre o índice ROX e a PaO2/FiO2 final. Baixos valores do índice ROX foram associados a um maior risco de intubação.
Downloads
Referências
Ranzani OT, Bastos LSL, Gelli JGM, et al. Characterisation of the first 250,000 hospital admissions for COVID-19 in Brazil: a retrospective analysis of nationwide data. Lancet Respir Med. 2021;9(4):407-418. doi:10.1016/S2213-2600(20)30560-9
Grasselli G, Pesenti A, Cecconi M. Critical Care Utilization for the COVID-19 Outbreak in Lombardy, Italy: Early Experience and Forecast During an Emergency Response. JAMA. 2020;323(16):1545-1546. doi:10.1001/jama.2020.4031
Calligaro GL, Lalla U, Audley G, et al. The utility of high-flow nasal oxygen for severe COVID-19 pneumonia in a resource-constrained setting: A multi-centre prospective observational study. EClinicalMedicine. 2020 Nov;28:100570. doi: 10.1016/j.eclinm.2020.100570.
Vianello A, Arcaro G, Molena B, Turato C, Sukthi A, Guarnieri G. High-flow nasal cannula oxygen therapy to treat patients with hypoxemic acute respiratory failure consequent to SARS-CoV-2 infection. Thorax. 2020 Nov;75(11):998–1000. doi: 10.1136/thoraxjnl-2020-214993.
Franco C, Facciolongo N, Tonelli R, Dongilli R, Vianello A, Pisani L. Feasibility and clinical impact of out-of-ICU noninvasive respiratory support in patients with COVID-19-related pneumonia. Eur Respir J. 2020 Nov 5;56(5) doi: 10.1183/13993003.02130-2020.
Patel M, Gangemi A, Marron R, Chowdhury J, Yousef I, Zheng M. Retrospective analysis of high flow nasal therapy in COVID-19-related moderate-to-severe hypoxaemic respiratory failure. BMJ Open Respir Res. 2020 Aug;7(1) doi: 10.1136/bmjresp-2020-000650.
Vega ML, Pisani L. Nasal high flow oxygen in acute respiratory failure. Pulmonology. 2021 Feb 13 doi: 10.1016/j.pulmoe.2021.01.005. S2531-0437(21)00038-6https://doi.org/Epubahead of print.
Tonetti T, Grasselli G, Zanella A, Pizzilli G, Fumagalli R, Piva S. COVID-19 Northern Italian ICU Network. Use of critical care resources during the first 2 weeks (February 24-March 8, 2020) of the Covid-19 outbreak in Italy. Ann Intens Care. 2020 Oct 12;10(1):133. doi: 10.1186/s13613-020-00750-z.
Coppadoro, A., Benini, A., Fruscio, R. et al. Helmet CPAP to treat hypoxic pneumonia outside the ICU: an observational study during the COVID-19 outbreak. Crit Care. 2021; 25:80.
Holanda MA, Tomaza BS, Menezesa DGA, Linoa JA, Gomesa GC. ELMO 1.0: a helmet interface for CPAP and high-flow oxygen delivery. J Bras Pneumol. 2021;47(3):e20200590.
Nishimura M. High-Flow Nasal Cannula Oxygen Therapy in Adults: Physiological Benefits, Indication, Clinical Benefits, and Adverse Effects. Respiratory Care. 2016; 61(4): 529-54.
Kang BJ, Koh Y, Lim CM, Huh JW, Baek S, Han M. Failure of high-flow nasal cannula therapy may delay intubation and increase mortality. Intens Care Med. 2015 Apr;41(4):623–632. doi: 10.1007/s00134-015-3693-5.
Suliman LA, Abdelgawad TT, Farrag NS, Abdelwahab HW. Validity of ROX index in prediction of risk of intubation in patients with COVID-19 pneumonia. Adv Respir Med. 2021;89(1):1-7. doi: 10.5603/ARM.a2020.0176.
Roca O, Messika J, Caralt B, García-de-Acilu M, Sztrymf B, Ricard JD. Predicting success of high-flow nasal cannula in pneumonia patients with hypoxemic respiratory failure: the utility of the ROX index. J Crit Care. 2016 Oct;35:200–205. doi: 10.1016/j.jcrc.2016.05.022.
Blez D, Soulier A, Bonnet F, et al. Monitoring of high-flow nasal cannula for SARS-CoV-2 severe pneumonia: less is more, better look at respiratory rate. Intensive Care Med. 2020; 46(11): 2094–2095.
Roca O, Messika J, Caralt B, et al. Predicting success of high-flow nasal cannula in pneumonia patients with hypoxemic respiratory failure: The utility of the ROX index. J Crit Care. 2016; 35: 200–205.
Roca O, Caralt B, Messika J, et al. An index combining respiratory rate and oxygenation to predict outcome of nasal high-flow therapy. Am J Respir Crit Care Med. 2019; 199(11): 1368–1376.
Hill NS, Ruthazer R. Predicting outcomes of high-flow nasal cannula for acute respiratory distress syndrome. An index that ROX. Am J Respir Crit Care Med. 2019; 199(11): 1300–1302.
Rodriguez M, Thille AW, Boissier F, et al. Predictors of successful separation from high-flow nasal oxygen therapy in patients with acute respiratory failure: a retrospective monocenter study. Ann Intensive Care. 2019; 9(1): 101.
Hu M, Zhou Q, Zheng R, Li X, Ling J, Chen Y, Jia J, Xie C. Application of high-flow nasal cannula in hypoxemic patients with COVID-19: a retrospective cohort study. BMC Pulm Med. 2020 Dec 24;20(1):324. doi: 10.1186/s12890-020-01354-w
Downloads
Publicado
Como Citar
Edição
Seção
Categorias
Licença
Copyright (c) 2021 Cadernos ESP
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Accepted 2021-09-29
Published 2021-12-07
